Takeda Pharmaceutical (TAK) EBT (2017 - 2026)

Takeda Pharmaceutical has reported EBT for 10 years, with the latest figure at $1.0 billion in Q2 2026.

• On a quarterly basis, EBT fell 1.93% year-over-year to $1.0 billion in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 61.94% decrease from a year earlier, with the FY2026 full-year figure at -$907.7 million, down 178.97% from the prior year.
• EBT was $1.0 billion for Q2 2026 at Takeda Pharmaceutical, down from $1.0 billion in the prior quarter.
• The five-year high for EBT was $2.3 billion in Q3 2023, with the low at -$3.0 billion in Q4 2025.
• Average EBT over 5 years is $852.0 million, with a median of $1.0 billion recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: EBT soared 384.77% in 2023, then sank 318.9% in 2025.
• Over 5 years, EBT stood at $758.5 million in 2022, then tumbled by 57.27% to $324.1 million in 2023, then slumped by 317.8% to -$705.8 million in 2024, then tumbled by 318.9% to -$3.0 billion in 2025, then surged by 134.53% to $1.0 billion in 2026.
• The last three EBT figures came in at $1.0 billion (Q2 2026), $1.0 billion (Q1 2026), and -$3.0 billion (Q4 2025), per Business Quant data.